Find Clinical Trials

193 Results

Protocol Code	Study Title	Active substance/Medical device	Study Phase	Therapeutic Area
CL2-33138-011	A randomised, double-blind, placebo- and olanzapine- controlled, parallel-group study to evaluate the efficacy and safety…	S033138	Phase 2	Neuropsychiatric Diseases
CL2-33138-007	Safety and efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms:…	S033138	Phase 2	Neuropsychiatric Diseases
CL2-20098-075	Pharmacokinetics and safety of agomelatine in children (from 7 to less than 12 years) and…	AGOMELATINE, S020098	Phase 2	Neuropsychiatric Diseases
CL2-20098-072	Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of…	AGOMELATINE, S020098	Phase 2	Neuropsychiatric Diseases
CL2-20098-067	Effect of agomelatine (25 mg) given orally once a day for 7 days on cerebral…	AGOMELATINE, S020098	Phase 2	Neuropsychiatric Diseases
CL2-20098-040	Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally…	AGOMELATINE, S020098	Phase 2	Neuropsychiatric Diseases
CL2-18986-009	Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild…	S018986	Phase 2	Neuropsychiatric Diseases
CL2-18886-031	Effects of S 18886 on platelet function in type 2 diabetic patients treated by low-dose…	TERUTROBAN, S018886	Phase 2	Metabolism
CL2-18886-026	Effects of terutroban versus aspirin on composition of atherosclerotic plaque in patients undergoing a carotid…	TERUTROBAN, S018886	Phase 2	Cardiovascular Diseases
CL2-16257-101	Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-099	Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-096	Effects of oral chronic administration of ivabradine (7.5 mg bid) in comparison to placebo (bid)…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-095	Effects of oral administration of ivabradine (7.5 mg bid) on post-ischaemic stunning induced by exercise…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-090	Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-088	Effects of ivabradine IV versus placebo on haemodynamic parameters in patients with a low cardiac…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-073	Evaluation of the effects of oral administration of ivabradine 5 mg and 7.5 mg b.i.d.…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-062	Evaluation of the effects of 3 successive oral dosages (2.5, 5, 7.5 mg b.i.d.) of…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-060	Evaluation of the effects on heart rate, haemodynamic parameters, safety and tolerability of 5 mg…	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-16257-053	Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure	IVABRADINE, S016257	Phase 2	Cardiovascular Diseases
CL2-12911-039	A double-blind, multicenter, international randomised study to assess the effects of 4 month-oral administration of…	STRONTIUM RANELATE, S012911	Phase 2	Rheumatology
CL2-09490-157	Assessment of the effects on 24-hour ambulatory blood pressure and the safety of a once-a-day…	PERINDOPRIL TERT BUTYLAMINE, S009490	Phase 2	Cardiovascular Diseases
CL2-066913-002	A randomized, double blind, placebo-controlled, parallel, international multicenter study assessing the efficacy of S066913 in…	S066913	Phase 2	Cardiovascular Diseases
CL2-05985-005	Efficacy and safety of the fixed oral low-dose perindopril arginine 3.5 mg/amlodipine 2.5 mg combination…	AMLODIPINE, PERINDOPRIL ARGININE, S005985	Phase 2	Cardiovascular Diseases
CL2-05720-005	Efficacy and safety assessment of two schemes of oral administration of once-daily extended release metformin…	GLICLAZIDE, METFORMINE, S005720	Phase 2	Metabolism
CL2-05682-102	Impact of Daflon 500 mg on the progression of chronic venous disease and symptoms in…	MICRONISED PURIFIED FLAVONOID FRACTION, S005682	Phase 2	Cardiovascular Diseases